Karas Eric 4
4 · ARS Pharmaceuticals, Inc. · Filed Mar 21, 2025
Insider Transaction Report
Form 4
Karas Eric
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-03-20$1.50/sh+10,000$15,000→ 17,696 total - Sale
Common Stock
2025-03-20$14.00/sh−10,000$140,000→ 7,696 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-03-20−10,000→ 574,588 totalExercise: $1.50Exp: 2032-05-23→ Common Stock (10,000 underlying)
Footnotes (3)
- [F1]Includes 2,003 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024.
- [F2]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.
- [F3]Immediately exercisable.